NCT05318755View on ClinicalTrials.gov

China Gender-affirming Hormone Therapy Study

RecruitingOBSERVATIONAL
Enrollment

240

Participants

Timeline

Start Date

April 16, 2022

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
TransgenderGender Incongruence
Interventions
DRUG

GAHT for transgender men

Testosterone undecanoate

DRUG

GAHT for transgender women

Estradiol and antiandrogens (Spironolactone or Cyproterone acetate)

Trial Locations (1)

100191

RECRUITING

Peking University Third Hospital, Beijing

All Listed Sponsors
collaborator

Tsinghua University

OTHER

lead

Peking University Third Hospital

OTHER